Media coverage about Irhythm Technologies (NASDAQ:IRTC) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Irhythm Technologies earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.6207701719604 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Vijay K. Lathi Sells 114,018 Shares of Irhythm Technologies Inc (IRTC) Stock (americanbankingnews.com)
- Canaccord Genuity Reaffirms “Positive” Rating for Irhythm Technologies (IRTC) (americanbankingnews.com)
- Irhythm Technologies Inc (IRTC) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Insider Selling: Irhythm Technologies Inc (IRTC) EVP Sells 935 Shares of Stock (americanbankingnews.com)
Shares of Irhythm Technologies (NASDAQ IRTC) traded down $0.34 during trading hours on Wednesday, hitting $64.18. The stock had a trading volume of 94,327 shares, compared to its average volume of 231,772. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.64 and a current ratio of 5.72. The stock has a market capitalization of $1,562.11, a PE ratio of -49.42 and a beta of 0.98. Irhythm Technologies has a 1 year low of $32.10 and a 1 year high of $68.07.
A number of brokerages have weighed in on IRTC. Northland Securities reissued a “hold” rating and issued a $60.00 target price on shares of Irhythm Technologies in a research report on Wednesday. Canaccord Genuity reiterated a “buy” rating and set a $80.00 price objective (up from $68.00) on shares of Irhythm Technologies in a research note on Monday. JPMorgan Chase & Co. boosted their price objective on Irhythm Technologies from $62.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. BMO Capital Markets initiated coverage on Irhythm Technologies in a research note on Monday, March 5th. They issued an “outperform” rating and a $76.00 price target for the company. Finally, BidaskClub upgraded Irhythm Technologies from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $69.29.
In related news, Director Vijay K. Lathi sold 114,018 shares of the business’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $66.44, for a total value of $7,575,355.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP David A. Vort sold 935 shares of the company’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $67.01, for a total value of $62,654.35. Following the sale, the executive vice president now owns 22,221 shares in the company, valued at approximately $1,489,029.21. The disclosure for this sale can be found here. Insiders sold 395,362 shares of company stock worth $25,152,594 over the last ninety days. Corporate insiders own 23.30% of the company’s stock.
Irhythm Technologies Company Profile
iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.